Literature DB >> 15837155

The use of systemic immune moderators in dermatology: an update.

Dana Kazlow Stern1, Jackie M Tripp, Vincent C Ho, Mark Lebwohl.   

Abstract

In addition to corticosteroids, dermatologists have access to an array of immunomodulatory therapies. Azathioprine, cyclophosphamide, methotrexate, cyclosporine, and mycophenolate mofetil are the systemic immunosuppressive agents most commonly used by dermatologists. In addition, new developments in biotechnology have spurred the development of immunobiologic agents that are able to target the immunologic process of many inflammatory disorders at specific points along the inflammatory cascade. Alefacept, efalizumab, etanercept, and infliximab are the immunobiologic agents that are currently the most well known and most commonly used by dermatologists. This article reviews the pharmacology, mechanism of action, side effects, and clinical applications of these therapies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15837155     DOI: 10.1016/j.det.2004.09.006

Source DB:  PubMed          Journal:  Dermatol Clin        ISSN: 0733-8635            Impact factor:   3.478


  5 in total

1.  Editorial: cytokine inhibition for treatment of Alzheimer's disease.

Authors:  Paul B Rosenberg
Journal:  MedGenMed       Date:  2006-04-26

2.  Role of methotrexate in the treatment of bullous pemphigoid in the elderly.

Authors:  Timothy Patton; Neil Korman
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

3.  Epithelial-myoepithelial parotid carcinoma after kidney transplantation.

Authors:  R Horta; F Barreto; M Marques; M Rebelo; J C Reis; J M Lopes; J M Amarante
Journal:  Ecancermedicalscience       Date:  2008-08-21

4.  Haplotypes of ABCB1 1236C >T (rs1128503), 2677G >T/A (rs2032582), and 3435C >T (rs1045642) in patients with bullous pemphigoid.

Authors:  Mariola Rychlik-Sych; Małgorzata Barańska; Michał Dudarewicz; Jadwiga Skrętkowicz; Agnieszka Żebrowska; Anna Woźniacka; Jacek Owczarek; Daria Orszulak-Michalak; Elżbieta Waszczykowska
Journal:  Arch Dermatol Res       Date:  2018-06-09       Impact factor: 3.017

5.  Biologics in dermatologic therapy - an update.

Authors:  Arijit Coondoo
Journal:  Indian J Dermatol       Date:  2009-07       Impact factor: 1.494

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.